

BIOCON GROUP

FACT SHEET

September-12

H1 FY 2013 vs. H1 FY 2012

Q2 FY 2013 vs. Q2 FY 2012

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
BALANCE SHEET**

(Rs. Crores)

	September 30, 2012	March 31, 2012
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	2,347	2,172
	2,447	2,272
Minority interest	4	4
Non-current liabilities		
(a) Long-term borrowings	125	70
(b) Deferred tax liability (net)	39	-
(c) Other long-term liabilities	450	583
(d) Long-term provisions	4	-
	618	653
Current liabilities		
(a) Short-term borrowings	129	187
(b) Trade payables	311	348
(c) Other current liabilities	364	269
(d) Short-term provisions	68	212
	872	1,016
TOTAL	3,941	3,945
ASSETS		
Non-current assets		
(a) Fixed assets	1,683	1,648
(b) Good will on consolidation	12	12
(c) Non-current investments	78	64
(d) Deferred tax asset (net)	-	8
(e) Long term loans and advances	206	185
(f) Other non-current assets	186	29
	2,165	1,946
Current assets		
(a) Current Investments	406	492
(b) Inventories	405	378
(c) Trade receivables	503	492
(d) Cash and cash equivalents	341	523
(e) Short term loans and advances	82	79
(f) Other current assets	39	35
	1,776	1,999
TOTAL	3,941	3,945

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT** (Rs. Crores)

Particulars	H1 FY 13	H1 FY 12	Variance
INCOME			
Biopharmaceuticals	734	640	15%
Branded formulations - India	178	122	45%
Total Biopharmaceuticals	912	762	20%
Contract research	252	180	40%
Total Sales	1,164	942	24%
Other income	71	59	20%
Total Revenue	1,235	1,001	23%
EXPENDITURE			
Material & Power Costs	570	449	27%
Staff costs	172	137	26%
Research & Development	79	51	54%
Other Expenses	109	83	31%
Manufacturing, staff & other expenses	930	720	29%
PBDIT /EBITDA	305	281	8%
Interest and finance charges	4	7	-36%
Depreciation & Amortisation	88	88	-1%
PBT	213	186	14%
Taxes	43	30	44%
NET PROFIT FOR THE PERIOD	170	156	9%
Minority Interest	1	-	-
NET PROFIT FOR THE PERIOD, AFTER MINORITY	169	156	8%
EPS Rs.	8.5	7.8	
<i>Note: 1. The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
<i>2. Figures of the Comparative period have been regrouped wherever necessary</i>			
Biopharmaceuticals Income includes:			
Licensing development fees	-	51	
Licensing Income	14	-	

BIOCON LIMITED (CONSOLIDATED) UNAUDITED			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q2 FY 13	Q2 FY 12	Variance
<u>INCOME</u>			
Biopharmaceuticals	372	345	8%
Branded formulations - India	91	65	42%
Total Biopharmaceuticals	463	410	13%
Contract research	129	93	39%
Total Sales	592	503	18%
Other income	50	35	43%
Total Revenue	642	538	19%
<u>EXPENDITURE</u>			
Material & Power Costs	291	237	23%
Staff costs	88	72	22%
Research & Development	43	31	40%
Other Expenses	54	49	9%
Manufacturing, staff & other expenses	476	389	22%
PBDIT /EBITDA	166	149	11%
Interest and finance charges	1	2	-39%
Depreciation & Amortisation	45	42	4%
PBT	120	105	15%
Taxes	30	19	62%
NET PROFIT FOR THE PERIOD	90	86	5%
Minority Interest	-	-	-
NET PROFIT FOR THE PERIOD, AFTER MINORITY	90	86	5%
EPS Rs.	4.5	4.3	
<p>Note: 1. The figures are rounded off to the nearest crores, percentages are based on absolute numbers</p> <p>2. Figures of the Comparative period have been regrouped wherever necessary</p>			
Biopharmaceuticals Income includes:			
Licensing development fees	-	37	
Licensing Income	-	-	